Rosuvastatin: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
{| class="wikitable" border="1" width="48%" style="text-align:center" | {| class="wikitable" border="1" width="48%" style="text-align:center" | ||
|- | |- | ||
! colspan="6" align="center"| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref> | ! colspan="6" align="center"| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref> <ref>PMID:12895195</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 23: | Line 23: | ||
! [[Simvastatin]] (Zocor) | ! [[Simvastatin]] (Zocor) | ||
! [[Rosuvastatin]] (Crestor) | ! [[Rosuvastatin]] (Crestor) | ||
! [[Cerivastatin]] (Baycol) | |||
|- | |- | ||
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
| Line 30: | Line 31: | ||
! 1.5 | ! 1.5 | ||
! 4 | ! 4 | ||
! 1.5 | |||
|- | |- | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
| Line 36: | Line 38: | ||
! 10-20 | ! 10-20 | ||
! 7.3 | ! 7.3 | ||
!4.34 | ! 4.34 | ||
! 3.43 | |||
|- | |- | ||
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| Line 44: | Line 47: | ||
! 5 | ! 5 | ||
! 20 | ! 20 | ||
! 60 | |||
|- | |- | ||
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%) | ||
| Line 51: | Line 55: | ||
! 95 | ! 95 | ||
! 88 | ! 88 | ||
! 99 | |||
|- | |- | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
| Line 58: | Line 63: | ||
! 2.7 | ! 2.7 | ||
! 19 | ! 19 | ||
! 2.2 | |||
|- | |- | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
| Line 65: | Line 71: | ||
! 125 | ! 125 | ||
! 48 | ! 48 | ||
! 14.5 | |||
|- | |- | ||
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
| Line 72: | Line 79: | ||
! 66 | ! 66 | ||
! 320 | ! 320 | ||
! 50-90 | |||
|- | |- | ||
! Equivalent LDL Reduction Dosage (mg) | ! Equivalent LDL Reduction Dosage (mg) | ||
| Line 79: | Line 87: | ||
! 20 | ! 20 | ||
! 5 | ! 5 | ||
! -- | |||
|- | |- | ||
! Metabolism | ! Metabolism | ||
| Line 86: | Line 95: | ||
! Hepatic <br/>(CYP3A4) | ! Hepatic <br/>(CYP3A4) | ||
! Not <br/>Metabolized | ! Not <br/>Metabolized | ||
! Hepatic <br />(CYP2C8) | |||
|} | |} | ||